Pertussis antibodies and uses thereof

Abstract

Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.

1 .- 65 . (canceled) 
     
     
         66 . A humanized 1B7 antibody comprising a humanized light chain variable region and a humanized heavy chain variable region,
 wherein said humanized light chain variable region comprises:
 (i) a mouse CDR L1 as set forth in SEQ ID NO:3, a mouse CDR L2 as set forth in SEQ ID NO:4, a mouse CDR L5 as set forth in SEQ ID NO:5 and 
 (ii) a tyrosine at a position corresponding to Kabat position 71, a serine at a position corresponding to Kabat position 10, a leucine at a position corresponding to Kabat position 11, a glycine at a position corresponding to Kabat position 16, an arginine at a position corresponding to Kabat position 18, a glycine at a position corresponding to Kabat position 41, a lysine at a position corresponding to Kabat position 42, or a leucine at a position corresponding to Kabat position 47; and 
   wherein said humanized heavy chain variable region comprises:
 (iii) a mouse CDR H1 as set forth in SEQ ID NO:6, a mouse CDR H2 as set forth in SEQ ID NO:7, and a mouse CDR H3 as set forth in SEQ ID NO:8 and 
 (iv) a valine at a position corresponding to Kabat position 71, an arginine at a position corresponding to Kabat position 38, an alanine at a position corresponding to Kabat position 40, or a valine at a position corresponding to Kabat position 109. 
   
     
     
         67 . The humanized 1B7 antibody of  claim 66 , wherein said humanized light chain variable region comprises a tyrosine at a position corresponding to Kabat position 71 and said humanized heavy chain variable region comprises a valine at a position corresponding to Kabat position 71. 
     
     
         68 . The humanized 1B7 antibody of  claim 66 , wherein said antibody is a Fab′ fragment. 
     
     
         69 . The humanized 1B7 antibody of  claim 66 , wherein said antibody comprises a human constant region. 
     
     
         70 . The humanized 1B7 antibody of  claim 66 , wherein said antibody is an IgG. 
     
     
         71 . The humanized 1B7 antibody of  claim 66 , wherein said antibody is a single chain antibody (scFv). 
     
     
         72 . The humanized 1B7 antibody of  claim 66 , wherein said antibody is capable of binding a pertussis toxin protein with an equilibrium dissociation constant (K D ) less than 10 nM. 
     
     
         73 . The humanized 1B7 antibody of  claim 72 , wherein said pertussis toxin protein is a truncated pertussis toxin protein. 
     
     
         74 . The humanized 1B7 antibody of  claim 73 , wherein said truncated pertussis toxin protein comprises the amino acid sequence corresponding to amino acid residues 1 to 220 of SEQ ID NO:9. 
     
     
         75 . The humanized 1B7 antibody of  claim 66 , wherein said humanized antibody is an antibody which competes with an antibody that is capable of binding a pertussis toxin protein comprising the amino acid sequence corresponding to amino acid residues 1 to 220 of SEQ ID NO:9. 
     
     
         76 . A humanized antibody which binds the same epitope as the antibody set forth in  claim 66 . 
     
     
         77 . A pharmaceutical composition comprising a therapeutically effective amount of a humanized antibody as set forth in  claim 66 . 
     
     
         78 . An isolated nucleic acid encoding a humanized antibody as set forth in  claim 66 . 
     
     
         79 . A method of treating whooping cough in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a humanized antibody as set forth in  claim 66  and a pharmaceutically acceptable excipient, thereby treating whooping cough in the subject.